TLP
JANX icon

Tri Locum Partners’s Janux Therapeutics JANX Stock Holding History

Tri Locum Partners’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-236,407
Closed -$12.7M – 28
2024
Q4 		$12.7M Buy
+236,407
New +$12.5M 2.62% 17

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Tri Locum Partners's JANX Position: Q1 2025 in Review

Tri Locum Partners sold out of Janux Therapeutics (JANX) in Q1 2025, closing a stake of 236,407 shares — an estimated $12.7M sold.

Tri Locum Partners first reported a position in JANX in Q4 2024 and held it in 1 quarter. The position peaked at $12.7M in Q4 2024. 181 funds tracked by Wall St. Rank hold JANX as of Q1 2025.

  • Tri Locum Partners reported no remaining Janux Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Tri Locum Partners sold 236,407 Janux Therapeutics shares in Q1 2025, an estimated $12.7M.
  • Tri Locum Partners first reported a position in Janux Therapeutics in Q4 2024 and held it in 1 quarter.
  • Tri Locum Partners's Janux Therapeutics position peaked at $12.7M in Q4 2024.
  • 181 funds tracked by Wall St. Rank held Janux Therapeutics as of Q1 2025.

Based on Tri Locum Partners's 13F filing for Q1 2025, filed 14 May 2025.